Literature DB >> 31754069

Immune-Related Adverse Events in the Setting of PD-1/L1 Inhibitor Combination Therapy.

Leyre Zubiri1, Ian M Allen1, Martin S Taylor1, Amanda C Guidon1, Steven T Chen1, Sara R Schoenfeld1, Tomas G Neilan1, Meghan E Sise1, Meghan J Mooradian1, Krista M Rubin1, Rebecca Karp Leaf1, Aparna R Parikh1, Alexander Faje1, Justin F Gainor1, Justine V Cohen1, Florian J Fintelmann1, Minna J Kohler1, Michael Dougan1, Kerry L Reynolds2.   

Abstract

Keywords:  Immune checkpoint inhibitor; Immune‐related adverse events; Immunotherapy; Immunotherapy toxicity; PD‐1/L1 inhibitor

Year:  2019        PMID： 31754069     DOI： 10.1634/theoncologist.2018-0883

Source DB:  PubMed          Journal:  Oncologist        ISSN： 1083-7159


× No keyword cloud information.
  56 in total

1.  Nivolumab in previously untreated melanoma without BRAF mutation.

Authors:  Caroline Robert; Georgina V Long; Benjamin Brady; Caroline Dutriaux; Michele Maio; Laurent Mortier; Jessica C Hassel; Piotr Rutkowski; Catriona McNeil; Ewa Kalinka-Warzocha; Kerry J Savage; Micaela M Hernberg; Celeste Lebbé; Julie Charles; Catalin Mihalcioiu; Vanna Chiarion-Sileni; Cornelia Mauch; Francesco Cognetti; Ana Arance; Henrik Schmidt; Dirk Schadendorf; Helen Gogas; Lotta Lundgren-Eriksson; Christine Horak; Brian Sharkey; Ian M Waxman; Victoria Atkinson; Paolo A Ascierto
Journal:  N Engl J Med       Date:  2014-11-16       Impact factor: 91.245

2.  Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma.

Authors:  Alexander M M Eggermont; Christian U Blank; Mario Mandala; Georgina V Long; Victoria Atkinson; Stéphane Dalle; Andrew Haydon; Mikhail Lichinitser; Adnan Khattak; Matteo S Carlino; Shahneen Sandhu; James Larkin; Susana Puig; Paolo A Ascierto; Piotr Rutkowski; Dirk Schadendorf; Rutger Koornstra; Leonel Hernandez-Aya; Michele Maio; Alfonsus J M van den Eertwegh; Jean-Jacques Grob; Ralf Gutzmer; Rahima Jamal; Paul Lorigan; Nageatte Ibrahim; Sandrine Marreaud; Alexander C J van Akkooi; Stefan Suciu; Caroline Robert
Journal:  N Engl J Med       Date:  2018-04-15       Impact factor: 91.245

3.  Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma.

Authors:  Robert Chen; Pier Luigi Zinzani; Michelle A Fanale; Philippe Armand; Nathalie A Johnson; Pauline Brice; John Radford; Vincent Ribrag; Daniel Molin; Theodoros P Vassilakopoulos; Akihiro Tomita; Bastian von Tresckow; Margaret A Shipp; Yinghua Zhang; Alejandro D Ricart; Arun Balakumaran; Craig H Moskowitz
Journal:  J Clin Oncol       Date:  2017-04-25       Impact factor: 44.544

4.  Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.

Authors:  Achim Rittmeyer; Fabrice Barlesi; Daniel Waterkamp; Keunchil Park; Fortunato Ciardiello; Joachim von Pawel; Shirish M Gadgeel; Toyoaki Hida; Dariusz M Kowalski; Manuel Cobo Dols; Diego L Cortinovis; Joseph Leach; Jonathan Polikoff; Carlos Barrios; Fairooz Kabbinavar; Osvaldo Arén Frontera; Filippo De Marinis; Hande Turna; Jong-Seok Lee; Marcus Ballinger; Marcin Kowanetz; Pei He; Daniel S Chen; Alan Sandler; David R Gandara
Journal:  Lancet       Date:  2016-12-13       Impact factor: 79.321

5.  Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial.

Authors:  Andrew X Zhu; Richard S Finn; Julien Edeline; Stephane Cattan; Sadahisa Ogasawara; Daniel Palmer; Chris Verslype; Vittorina Zagonel; Laetitia Fartoux; Arndt Vogel; Debashis Sarker; Gontran Verset; Stephen L Chan; Jennifer Knox; Bruno Daniele; Andrea L Webber; Scot W Ebbinghaus; Junshui Ma; Abby B Siegel; Ann-Lii Cheng; Masatoshi Kudo
Journal:  Lancet Oncol       Date:  2018-06-03       Impact factor: 41.316

6.  Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.

Authors:  James Larkin; Vanna Chiarion-Sileni; Rene Gonzalez; Jean Jacques Grob; C Lance Cowey; Christopher D Lao; Dirk Schadendorf; Reinhard Dummer; Michael Smylie; Piotr Rutkowski; Pier F Ferrucci; Andrew Hill; John Wagstaff; Matteo S Carlino; John B Haanen; Michele Maio; Ivan Marquez-Rodas; Grant A McArthur; Paolo A Ascierto; Georgina V Long; Margaret K Callahan; Michael A Postow; Kenneth Grossmann; Mario Sznol; Brigitte Dreno; Lars Bastholt; Arvin Yang; Linda M Rollin; Christine Horak; F Stephen Hodi; Jedd D Wolchok
Journal:  N Engl J Med       Date:  2015-05-31       Impact factor: 91.245

7.  Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma.

Authors:  Jeffrey Weber; Mario Mandala; Michele Del Vecchio; Helen J Gogas; Ana M Arance; C Lance Cowey; Stéphane Dalle; Michael Schenker; Vanna Chiarion-Sileni; Ivan Marquez-Rodas; Jean-Jacques Grob; Marcus O Butler; Mark R Middleton; Michele Maio; Victoria Atkinson; Paola Queirolo; Rene Gonzalez; Ragini R Kudchadkar; Michael Smylie; Nicolas Meyer; Laurent Mortier; Michael B Atkins; Georgina V Long; Shailender Bhatia; Celeste Lebbé; Piotr Rutkowski; Kenji Yokota; Naoya Yamazaki; Tae M Kim; Veerle de Pril; Javier Sabater; Anila Qureshi; James Larkin; Paolo A Ascierto
Journal:  N Engl J Med       Date:  2017-09-10       Impact factor: 91.245

8.  Myocarditis Associated with Immune Checkpoint Inhibitors: An Expert Consensus on Data Gaps and a Call to Action.

Authors:  Tomas G Neilan; Mace L Rothenberg; Laleh Amiri-Kordestani; Ryan J Sullivan; Richard M Steingart; William Gregory; Subramanian Hariharan; Tarek A Hammad; JoAnn Lindenfeld; Martin J Murphy; Javid J Moslehi
Journal:  Oncologist       Date:  2018-05-25

9.  Diagnosis and Management of Hepatitis in Patients on Checkpoint Blockade.

Authors:  Kerry Reynolds; Molly Thomas; Michael Dougan
Journal:  Oncologist       Date:  2018-05-31

10.  Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial.

Authors:  Anas Younes; Armando Santoro; Margaret Shipp; Pier Luigi Zinzani; John M Timmerman; Stephen Ansell; Philippe Armand; Michelle Fanale; Voravit Ratanatharathorn; John Kuruvilla; Jonathon B Cohen; Graham Collins; Kerry J Savage; Marek Trneny; Kazunobu Kato; Benedetto Farsaci; Susan M Parker; Scott Rodig; Margaretha G M Roemer; Azra H Ligon; Andreas Engert
Journal:  Lancet Oncol       Date:  2016-07-20       Impact factor: 41.316
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.